Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.
Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.
Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.
Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.
Registry search results
Matching records; showing 19 on this page, newest registry updates first. Search checked 2026-11-08 18:08 UTC. Counts are registry matches, not unique peptides or a worldwide total.
GERCOR - Multidisciplinary Oncology Cooperative Group
Countries with listed sites
Belgium · France
Registry dates and results
Start: 2013-01-07. Completion: 2017-12 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Lanreotide (drug)
Placebo (for sunitinib) (drug)
Sunitinib (drug)
Where the study takes place — 20 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Cliniques Universitaires Saint LucBrussels, Belgium
Explore the world’s study registries
These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.
Start: 2011-07. Completion: 2014-12 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Lanreotide Autogel 120mg (drug)
Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Universital Hospital Ghent Ghent, Belgium Site recruitment: Not reported
Start: 2015-08. Completion: 2017-06 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Pasireotide LAR 60 mg (drug) — also listed as: Signifor, SOM230
Pegvisomant (drug) — also listed as: Somavert
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Erasmus Medical Center Rotterdam, South Holland, Netherlands Site recruitment: Not reported
Start: 2009-10. Completion: 2013-07 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Lanreotide (acetate) (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University Hospital Ghent Ghent, Belgium Site recruitment: Not reported
Start: 2011-05. Completion: 2014-06 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Lanreotide (drug) — also listed as: Somatuline
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Radboud University Hospital Nijmegen, Gelderland, Netherlands Site recruitment: Not reported
Start: 2011-03. Completion: 2014-07 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Lanreotide Autogel 90 mg and 120 mg (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
UZ Leuven, Gasthuisberg Leuven, Provincie Vlaams-Brabant, Belgium Site recruitment: Not reported
Start: 2014-04. Completion: 2016-04 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Lanreotide (drug) — also listed as: Somatuline
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University Hospital of Brussels Jette, Belgium Site recruitment: Not reported
Start: 2008-06. Completion: 2011-05 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Pegvisomant (drug) — also listed as: Somavert
Somatostatin analog (lanreotide or octreotide) (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Department of Endocrinology, Aarhus University Hospital Aarhus C, Aarhus, Denmark Site recruitment: Not reported
Start: 2008-03. Completion: 2011-12 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Lanreotide LP 90 (drug)
Placebo lanreotide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Hôpital Mère Enfant- CHU de Limoges Limoges, France Site recruitment: Not reported
Start: 2004-01. Completion: 2010-12 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Preoperative lanreotide treatment (drug)
Transsphenoidal surgery (procedure)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China Site recruitment: Recruiting
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
D. Cotugno Hospital Naples, Italy Site recruitment: Not reported
Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Blood draw (other)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Cedars-Sinai Medical Center Los Angeles, California, United States Site recruitment: Recruiting
Start: 2007-10. Completion: Not reported (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Placebo (drug)
Lanreotide (drug)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University Hospital Gasthuisberg Leuven, Belgium Site recruitment: Not reported
Radboud University Medical Center Nijmegen, Netherlands Site recruitment: Not reported
Start: 2008-04. Completion: 2009-08 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
lanreotide (drug)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University Hospital Gasthuisberg, University of Leuven Leuven, Belgium Site recruitment: Not reported
Radboud University Nijmegen Medical Center Nijmegen, Netherlands Site recruitment: Not reported
Start: 1997-01. Completion: 2008-06 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Octreotide-LAR or lanreotide (drug) — also listed as: Sandostatin-LAR (Novartis), Ipstyl (Ipsen)
Transsphenoidal adenomectomy (procedure)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples Naples, Italy Site recruitment: Not reported
Start: 2003-01. Completion: 2007-12 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Lanreotide-Autogel 120 mg (drug) — also listed as: Ipstyl
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Annamaria Colao Naples, Italy Site recruitment: Not reported
Start: 1997-01. Completion: 2007-12 (may be estimated). No results posted in this registry response.
Products and interventions (0)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples Naples, Naples, Italy Site recruitment: Not reported
Start: 2007-10. Completion: Not reported (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Somatuline (Lanreotide Autogel®) (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
UMC St. Radboud Medical Center Nijmegen, Gelderland, Netherlands Site recruitment: Recruiting
Start: 2002-09. Completion: 2004-12 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Lanreotide Autogel and Octreotide LAR (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Department of Endocrinology, Odense University Hospital Odense, Funen, Denmark Site recruitment: Not reported
Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.